LGVN - Longeveron Inc - Ordinary Shares - Class A
IEX Last Trade
2.045
-0.045 -2.200%
Share volume: 362,317
Last Updated: Fri 30 Aug 2024 09:59:57 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$2.09
-0.05
-2.15%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-12 | 2022-11-14 | 2023-03-14 | 2023-05-12 | 2023-08-11 | 2023-11-09 | 2024-02-27 | 2024-05-14 | |
| Assets | |||||||||
| Total Assets | 35.325 M | 30.515 M | 27.413 M | 21.808 M | 17.093 M | 11.625 M | 12.078 M | 9.697 M | |
| Current Assets | 28.238 M | 23.237 M | 20.280 M | 14.870 M | 10.292 M | 5.044 M | 5.848 M | 3.757 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 1.041 M | 744.000 K | 404.000 K | 1.097 M | 1.539 M | 1.015 M | 376.000 K | 1.288 M | |
| Short Term Investments | 1.041 M | 744.000 K | 404.000 K | 1.097 M | 1.539 M | 1.015 M | 376.000 K | 1.288 M | |
| Total Receivables | 136.000 K | 177.000 K | 218.000 K | 96.000 K | 96.000 K | 96.000 K | 111.000 K | 178.000 K | |
| Current Cash | 27.061 M | 22.316 M | 19.658 M | 13.677 M | 8.657 M | 3.933 M | 5.361 M | 2.291 M | |
| Total Non-current Assets | 7.087 M | 7.278 M | 7.133 M | 6.938 M | 6.801 M | 6.581 M | 6.230 M | 5.940 M | |
| Property Plant Equipment | 2.835 M | 3.064 M | 2.949 M | 2.810 M | 2.717 M | 2.544 M | 2.529 M | 2.348 M | |
| Other Assets | 1.894 M | 1.841 M | 1.775 M | 1.703 M | 1.602 M | 1.498 M | 1.414 M | 1.329 M | |
| Intangible Assets | 2.358 M | 2.373 M | 2.409 M | 2.425 M | 2.482 M | 2.539 M | 2.287 M | 2.263 M | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 35.325 M | 30.515 M | 27.413 M | 21.808 M | 17.093 M | 11.625 M | 12.078 M | 9.697 M | |
| Total liabilities | 5.944 M | 5.900 M | 6.910 M | 5.490 M | 5.830 M | 4.993 M | 5.337 M | 6.656 M | |
| Total current liabilities | 3.618 M | 3.715 M | 4.869 M | 3.595 M | 4.082 M | 3.394 M | 3.889 M | 5.295 M | |
| Accounts Payable | 327.000 K | 527.000 K | 1.751 M | 457.000 K | 1.700 M | 829.000 K | 638.000 K | 1.467 M | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 1.448 M | 66.000 K | |
| Current long term debt | 550.000 K | 557.000 K | 564.000 K | 571.000 K | 578.000 K | 586.000 K | 593.000 K | 601.000 K | |
| Long term debt | 2.326 M | 2.185 M | 2.041 M | 1.895 M | 1.748 M | 1.599 M | 0.000 | 1.295 M | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 1.448 M | 66.000 K | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 29.381 M | 24.615 M | 20.503 M | 16.318 M | 11.263 M | 6.632 M | 6.741 M | 3.041 M | |
| Common stock | 20.944 M | 21.002 M | 21.019 M | 21.034 M | 21.105 M | 21.179 M | 2.362 M | 2.514 M | |
| Retained earnings | -53.072 M | -58.316 M | -62.773 M | -67.420 M | -73.052 M | -78.956 M | -84.984 M | -89.042 M |